Account
Articles
24.10.2018
Patient access to high-cost orphan drugs

Orphan drugs have important societal value as they improve patient quality of life and address unmet...

Read more
Articles
24.08.2018
Treatment for rare conditions

Faster access to new treatments for very rare conditions announced following a revised decision maki...

Read more
Articles
05.07.2017
No confidential discounts in Germany

Introduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...

Read more
Articles
13.10.2016
German pricing and market access laws

The German Ministry of Health has recently published its final bill concerning pricing and market ac...

Read more
Articles
15.01.2016
Cost effective HTA evaluations

The methodology to be used within the cost-effectiveness HTA evaluations is likely to be based on a ...

Read more
Articles
03.03.2015
The rise of speciality products

Pharmaceutical companies are able to charge significantly higher prices as these products are addres...

Read more
Articles
21.11.2014
Presentation to EUCOPE members by Remap Consulting

Remap Consulting presents NICE's highly specialised technology methodology to EUCOPE

Read more
News
02.10.2014
Incl. latest news on NICE's Value Based Assessment

Updates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.